Cargando…
Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients
Autores principales: | How, Joan, Gallagher, Kathleen M. E., Liu, Yiwen, Katsis, Katelin, Elder, Eva L., Larson, Rebecca C., Leick, Mark B., Neuberg, Donna, Maus, Marcela V., Hobbs, Gabriela S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873343/ https://www.ncbi.nlm.nih.gov/pubmed/35217807 http://dx.doi.org/10.1038/s41375-022-01533-0 |
Ejemplares similares
-
Antibody and T-Cell Responses to COVID-19 Vaccination in Myeloproliferative Neoplasm Patients
por: How, Joan, et al.
Publicado: (2021) -
Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections
por: How, Joan, et al.
Publicado: (2022) -
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients
por: How, Joan, et al.
Publicado: (2021) -
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
por: How, Joan, et al.
Publicado: (2020) -
SARS -CoV-2 T-cell immunity to variants of concern following vaccination
por: Gallagher, Kathleen M.E., et al.
Publicado: (2021)